NTRK1 and melanoma: The most frequently activating mutation is in the BRAF kinase representing about 35% to 40% of melanomas.[2] The receptor tyrosine kinase c-Kit is less frequently mutated and seen mostly in mucosal and acral melanomas, and less often in melanomas with chronic sun-damaged skin.[3] The activating mutations can be blocked effectively with targeted therapies such as Imatinib.[4]